EQUITY RESEARCH - RESULTS FLASH



GENESIS FERTILITY CENTER

THAILAND / SERVICES - MAI

GFC TB

TARGET PRICE

UP/DOWNSIDE

TP vs CONSENSUS

CLOSE

UNCHANGED
THB8.20

THB7.20

+13.9%

-22.6%

3Q24 results at first glance

กำไรสุทธิ 3Q24 ต่ำกว่าเราคาดเล็กน้อย

Highlights

- GFC รายงานกำไรสุทธิ 3Q24 ที่ 15 ล้านบาท ลดลง 14% q-q และ 27% y-y ต่ำ กว่าเราคาด 4.5% จากค่าใช้จ่ายพนักงานที่สูงกว่าคาด
- รายได้รวมเพิ่มขึ้น 12.8% q-q และ 6% y-y จากจำนวนรอบเก็บไข่อยู่ที่ 255 รอบ เพิ่มขึ้นเล็กน้อย จาก 250 รอบใน 2Q24 แต่เพิ่มขึ้นจาก 242 รอบใน 3Q23 และ รายได้การให้บริการตรวจโครโมโซมเพิ่มขึ้นตามจำนวนรอบเก็บไข่ที่เพิ่ม ตามคาด
- ขณะที่ตันทุนการให้บริการเพิ่มขึ้นจากการเปิดสาขาอุบลราชธานีตั้งแต่เดือนส.ค. ที่
 ผ่านมา ส่งผลให้อัตรากำไรขั้นตันอยู่ที่ 46.7% ลดลงจาก 47.6% ใน 2Q24 และ
 48.5% ใน 3Q23 ตามคาด
- อีกทั้งค่าใช้จ่ายดำเนินงานและบริหารเพิ่มขึ้นทั้ง 27% q-q, 24% y-y จากการจ้าง พนักงานสาขาใหม่ที่เพิ่มขึ้นมากกว่าเราคาด

Outlook

- แนวโน้ม 4Q24 น่าจะทรง q-q จากภาพตลาด IVF ที่กำลังเผชิญกับการใช้จ่ายที่ ระมัดระวังมากขึ้นจากเศรษฐกิจที่ไม่สดใสและการแข่งขันที่มากขึ้นจากคู่แข่งราย ใหม่ทั้งในและต่างประเทศ แม้ความต้องการรักษาการมีบุตรยากปรับเพิ่มขึ้น ต่อเนื่องเฉลี่ยปีละ 10-14% เพราะปัจจุบันคนเราแต่งงานช้า ทำให้มีอัตราการเกิด ต่ำ หลายประเทศสนับสนุนการมีบุตรเพิ่ม เช่น จีน ญี่ปุ่นและไทย อีกทั้งไทยยังเป็น หมุดหมายของการรักษาผู้มีบุตรยากของโลก
- คงประมาณการกำไรสุทธิปี 2024 ที่ 82 ล้านบาท +6% y-y และปี 2025 อยู่ที่ 94 ล้านบาท +14.5% y-y จากการเปิดสาขาใหม่ สุวรรณภูมิ-พระรามเก้าใน 1Q25 พร้อมกับนำเอาเทคโนโลยีช่วยการเจริญพันธ์ ขยายห้อง LAB ที่เป็น มาตรฐานสากลเพื่อรองรับลูกค้าต่างชาติที่จะเข้ารับบริการเป็นปีแรก โดยแต่งตั้ง Agency เพื่อนำลูกค้าจากจีนทำ IVF ของ GFC ราคาเป้าหมาย 8.20 บาท คง คำแนะนำ "ถือ"

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	356	398	429	464
Net profit	77	82	94	104
EPS (THB)	0.35	0.37	0.43	0.47
vs Consensus (%)	-	(3.9)	3.6	(4.1)
EBITDA	117	121	138	154
Recurring net profit	77	82	94	104
Core EPS (THB)	0.35	0.37	0.43	0.47
EPS growth (%)	(14.2)	6.1	14.5	10.0
Core P/E (x)	20.4	19.3	16.8	15.3
Dividend yield (%)	1.8	2.0	2.1	2.4
EV/EBITDA (x)	11.1	11.0	9.9	9.2
Price/book (x)	2.8	2.8	2.7	2.6
Net debt/Equity (%)	(50.7)	(45.7)	(36.0)	(28.0)
ROE (%)	21.6	14.6	16.3	17.4



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	(8.9)	6.7	(33.9)
Relative to country (%)	(8.0)	(5.0)	(37.0)
Mkt cap (USD m)			46
3m avg. daily turnover (USD i	m)		0.1
Free float (%)			27
Major shareholder	Prof. Dr. Pita	ak Lao Krirk	Kiat (35%)
12m high/low (THB)			13.30/6.50
Issued shares (m)			220.00

Sources: Bloomberg consensus; FSSIA estimates



Songklod Wongchai

Fundamental Investment Analyst on Securities; License no. 018086 songklod.won@fssia.com, +66 2646 9970

Exhibit 1: GFC - 3Q24 results summary

Profit & Loss Statement	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24	3Q24	Chá	ange		- 9M24		2024E
Year to Dec 31	(THB m)	(q-q %)	(y-y %)	(THB m)	(y-y%)	(%24E)	(THB m)						
Revenue	86	81	87	101	109	82	93	12.8	5.9	284	70	71	398
Cost of services	44	42	45	51	54	43	49	14.7	9.6	147	70	70	210
Gross profit	42	39	42	50	54	39	43	10.7	2.0	137	69	73	188
Operating costs	16	17	18	21	18	18	22	27.4	24.3	58	80	71	82
Operating profit	26	22	24	30	36	21	21	(2.9)	(14.4)	79	62	74	106
Interest expense	3	3	3	1	0	0	1	na	na	1	(79)	39	3
Profit before tax	29	25	27	30	37	22	21	(2.1)	(21.2)	80	48	78	103
Tax	5	4	1	6	7	5	5	na	na	17	86	82	21
Reported net profit	19	16	21	22	29	17	15	(13.7)	(26.9)	61	77	74	82
Key Ratios (%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(ppt)		(%)
Gross margin	48.7	48.0	48.5	49.7	50.1	47.6	46.7	(0.9)	(1.8)	48.2	(1.0)		47.2
Net margin	22.0	19.2	23.5	29.1	33.5	26.2	22.5	(3.7)	(1.0)	27.8	(7.8)		20.7
SG&A / Sales	18.0	20.6	20.6	20.6	16.6	21.4	24.2	2.8	3.6	20.5	6.8		20.6
Effective tax rate	16.9	16.3	4.2	19.4	20.1	21.0	22.5	1.4	18.2	21.0	3.0		20.0

Sources: GFC; FSSIA estimates

Financial Statements

Genesis Fertility Center

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	276	356	398	429	464
Cost of goods sold	(146)	(182)	(210)	(229)	(247)
Gross profit	130	174	188	201	216
Other operating income	0	0	0	0	0
Operating costs	(48)	(71)	(82)	(80)	(84)
Operating EBITDA	97	117	121	138	154
Depreciation	(15)	(15)	(15)	(18)	(22)
Goodwill amortisation	0	0	0	0	0
Operating EBIT	82	103	106	121	132
Net financing costs	(2)	(9)	(3)	(3)	(3)
Associates	0	0	0	0	0
Recurring non-operating income	0	0	0	0	0
Non-recurring items	0	0	0	0	0
Profit before tax	80	93	103	118	129
Tax	(14)	(16)	(21)	(24)	(26)
Profit after tax	66	77	82	94	104
Minority interests	0	0	0	0	0
Preferred dividends	0	0	0	0	0
Other items	0	0	0	0	0
Reported net profit	66	77	82	94	104
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	66	77	82	94	104
Per share (THB)					
Recurring EPS *	0.41	0.35	0.37	0.43	0.47
Reported EPS	0.41	0.35	0.37	0.43	0.47
DPS	0.22	0.13	0.14	0.15	0.17
Diluted shares (used to calculate per share data)	160	220	220	220	220
Growth					
Revenue (%)	14.0	28.9	11.8	8.0	8.0
Operating EBITDA (%)	(2.5)	21.6	2.7	14.9	11.3
Operating EBIT (%)	(4.9)	25.0	3.2	14.1	9.8
Recurring EPS (%)	(5.7)	(14.2)	6.1	14.5	10.0
Reported EPS (%)	(5.7)	(14.2)	6.1	14.5	10.0
Operating performance					
Gross margin inc. depreciation (%)	47.1	48.8	47.2	46.7	46.7
Gross margin exc. depreciation (%)	52.3	53.0	50.9	50.9	51.4
Operating EBITDA margin (%)	35.0	33.0	30.3	32.2	33.2
Operating EBIT margin (%)	29.7	28.8	26.6	28.1	28.6
Net margin (%)	23.8	21.8	20.7	21.9	22.3
Effective tax rate (%)	18.0	17.1	20.0	20.0	20.0
Dividend payout on recurring profit (%)	53.3	36.9	37.7	34.9	36.4
Interest cover (X)	39.7	11.4	35.3	40.2	44.2
Inventory days	31.2	31.6	27.8	25.7	24.0
Debtor days	2.6	8.9	14.4	14.6	14.6
Creditor days	66.8	63.6	64.7	66.9	68.0
Operating ROIC (%)	48.2	33.4	31.3	30.5	27.9
ROIC (%)	39.6	30.2	28.4	27.8	25.7
ROE (%)	47.2	21.6	14.6	16.3	17.4
ROA (%)	22.5	16.2	13.1	14.5	15.4
* Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Intracytoplasmic Sperm Injection (ICSI)	195	195	280	302	326
Next generation sequencing (NGS)	47	67	72	78	84
Preliminary examination services	27	53	32	35	35
Oocyte freezing	6	39	12	13	14

Sources: Genesis Fertility Center; FSSIA estimates

Financial Statements

Genesis Fertility Center

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026
Recurring net profit	66	77	82	94	10
Depreciation	15	15	15	18	2
ssociates & minorities	0	5	0	0	
Other non-cash items	0	0	0	0	
Change in working capital	1	(5)	6	3	
Cash flow from operations	81	93	103	115	12
Capex - maintenance	(241)	(15)	(50)	(85)	(86
Capex - new investment	0	0	0	0	,,
let acquisitions & disposals	4	5	(3)	(2)	(2
Other investments (net)	0	0	0	0	(0)
cash flow from investing	(237)	(10)	(53)	(87)	(88)
Dividends paid	(35) 0	(29) 358	(31)	(33)	(38
equity finance Debt finance	179	(189)	(45)	(45)	(45
Other financing cash flows	119	(109)	(1)	(1)	(*
Cash flow from financing	144	141	(76)	(78)	(8:
lon-recurring cash flows			(70)	(70)	(0.
Other adjustments	0	0	0	0	
let other adjustments	0	Ŏ	0	0	
Novement in cash	(12)	224	(26)	(50)	(4:
ree cash flow to firm (FCFF)	(154.10)	91.97	53.62	30.90	43.8
ree cash flow to equity (FCFE)	22.93	(105.74)	49.82	27.14	40.1
		(1001111)			
Per share (THB)	(0.70)	0.40	0.01	0.44	
CFF per share	(0.70)	0.42	0.24	0.14	0.2
CFE per share Recurring cash flow per share	0.10 0.50	(0.48) 0.44	0.23 0.44	0.12 0.51	0.º 0.!
Recurring cash now per share	0.30	0.44	0.44	0.51	0.
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026
angible fixed assets (gross)	313	303	353	438	52
ess: Accumulated depreciation	(37)	(28)	(42)	(60)	(8)
angible fixed assets (net)	276	275	311	378	4
ntangible fixed assets (net)	0	0	0	0	
ong-term financial assets	0	0	0	0	
nvest. in associates & subsidiaries	0	0	0	0	
Cash & equivalents	85	309	283	233	1
√C receivable	3	15	17	18	
nventories	14	15	15	15	
Other current assets	2	1	1	1	
Current assets	104	339	315	266	2
Other assets	28	26	29	32	;
otal assets	408	641	655	675	7
Common equity	154	561	568	584	6
finorities etc.	0	5	5	5	
otal shareholders' equity	154	566	573	589	6
ong term debt	165	16	15	14	
Other long-term liabilities	2	3	3	4	
ong-term liabilities	166	19	19	18	
VC payable	26	32	37	40	4
Short term debt	46	6	6	6	
Other current liabilities	15	17	21	22	:
current liabilities	87	55	64	68	
otal liabilities and shareholders' equity	408	641	655	675	70
let working capital	(23)	(19)	(26)	(29)	(3
nvested capital	281	282	314	381	4
Includes convertibles and preferred stock which is being	treated as debt				
er share (THB)					
ook value per share	0.96	2.55	2.58	2.66	2.
angible book value per share	0.96	2.55	2.58	2.66	2.
inancial strength					
let debt/equity (%)	81.1	(50.7)	(45.7)	(36.0)	(28
let debt/total assets (%)	30.7	(44.8)	(40.0)	(31.4)	(24.
Current ratio (x)	1.2	6.1	5.0	3.9	(24.
CF interest cover (x)	12.1	(10.7)	17.6	10.0	14
		2023	2024E	2025E	202
aluation	2022			16.8	15
/aluation Recurring P/E (x) *	17.5	20.4	19.3		
/aluation Recurring P/E (x) * Recurring P/E @ target price (x) *	17.5 20.0	23.3	21.9	19.2	17
/aluation Recurring P/E (x) *	17.5			19.2 16.8	17
(aluation Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%)	17.5 20.0 17.5 3.0	23.3 20.4 1.8	21.9 19.3 2.0	19.2 16.8 2.1	17 15 2
/aluation Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x)	17.5 20.0 17.5	23.3 20.4	21.9 19.3	19.2 16.8	17 15 2
Aduation Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x)	17.5 20.0 17.5 3.0 7.5 7.5	23.3 20.4 1.8 2.8 2.8	21.9 19.3 2.0	19.2 16.8 2.1 2.7 2.7	
Aduation Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x)	17.5 20.0 17.5 3.0 7.5	23.3 20.4 1.8 2.8 2.8 11.1	21.9 19.3 2.0 2.8	19.2 16.8 2.1 2.7	17 15 2 2 2
Aduation Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x)	17.5 20.0 17.5 3.0 7.5 7.5	23.3 20.4 1.8 2.8 2.8	21.9 19.3 2.0 2.8 2.8	19.2 16.8 2.1 2.7 2.7	17 15 2 2

Sources: Genesis Fertility Center; FSSIA estimates

Disclaimer for ESG scoring

ESG score	Methodolog	У			Rating					
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process base from the ann	ed on the com nual S&P Globa	transparent, rules-based panies' Total Sustainabili al Corporate Sustainabilii anies within each industry	lity Scores resulting ty Assessment (CSA).	Sustainability A ESG Score of I	Assessment (C ess than 45% ny are disqual	the annual S&P (CSA) for DJSI. Co of the S&P Glob lified. The constitu iverse.	ompanies with al ESG Score	an S&P Globa of the highest	
Sustainability Investment List (THSI) by The Stock Exchange of Thailand (SET)	managing bu Candidates I 1) no irregulation of >150 up capital. S 70%; 2) inde- wrongdoing	usiness with tra must pass the ar trading of th shareholders, come key disque ependent direct related to CG,	ility in Environmental and ansparency in Governance preemptive criteria, with the board members and explained and combined holding criteria include: 1 tors and free float violatic, social & environmental internings in red for > 3 years	ce, updated annually. two crucial conditions: xecutives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' impacts; 4) equity in	nature of the relevant industry and materiality.					
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by t Thailand (SE	the Thai IOD, v	h in sustainable developn with support from the Sto ts are from the perspectiv s.	ock Exchange of	Good (80-89), and not rated for equitable treatr	3 for Good (70 or scores beloment of shareh 25%); 4) disclo	ories: 5 for Excel 0-79), 2 for Fair (6 w 50. Weightings nolders (weight 2 osure & transpare	60-69), 1 for P s include: 1) th 5% combined	ass (60-69), ne rights; 2) and); 3) the role of	
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment and transparent and tof five the criteria cover date (45%), circulation of sexercised. The and verifiability	e incorporated and sufficiently e CG componer AGM proceding and after the nufficient informate second assessing and 3) openne	which shareholders' rights into business operations y disclosed. All form imporents to be evaluated annures before the meeting (10%). (The first attion for voting; and 2) facilitation in the ease of attending mess for Q&A. The third involvees, resolutions and voting res	s and information is ortant elements of two utilly. The assessment (45%), at the meeting ssesses 1) advance ing how voting rights can be neetings; 2) transparency is the meeting minutes that	Very Good (90-		o four categories: r (80-89), and not			
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmen policies. The (Companies di Declaration of Certification, in managers and	nt of key control Certification is Ceciding to become Intent to kick off Including risk asset	Checklist include corruptions, and the monitoring and is good for three years. The a CAC certified member store an 18-month deadline to subsessment, in place of policy and ablishment of whistleblowing all stakeholders.)	and developing of tart by submitting a pmit the CAC Checklist for and control, training of	passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.					
Morningstar Sustainalytics	based on an risk is unman regulatory filing	assessment on aged. Sources gs, news and oth	sk rating provides an ove of how much of a compar s to be reviewed include corp her media, NGO reports/webs	ny's exposure to ESG orate publications and sites, multi-sector	more risk is uni	managed, the	score is the sum higher ESG risk	is scored.		
		ompany feedback uality & peer revi	k, ESG controversies, issuer i iews.	feedback on draft ESG	NEGL 0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+	
ESG Book	positioned to the principle helps explain over-weighti	o outperform o of financial ma n future risk-ac	sustainable companies the long term. The materiality including informance. Mat the higher materiality and the logical performance. Wat the higher materiality and the logical possis.	ethodology considers ation that significantly teriality is applied by	The total ESG scores using m	score is calcul ateriality-base	lated as a weight ed weights. The s ndicating better p	ed sum of the score is scaled	features	
<u>MSCI</u>	MSCI ESG r	atings aim to r	measure a company's mand laggards according to	anagement of financially their exposure to ESG ri	relevant ESG ris sks and how wel	ks and opport they manage	unities. It uses a those risks relat	rules-based m	nethodology to	
	AAA	8.571-10.000	0					•		
	AA	7.143-8.570	Leader:	leading its industry in m	anaging the most s	gnificant ESG ri	sks and opportunitie	∌S		
	Α	5.714-7.142	?							
	BBB	4.286-5.713	Average:	a mixed or unexception industry peers	al track record of ma	anaging the mos	st significant ESG ris	sks and opportu	nities relative to	
	ВВ	2.857-4.285	j							
	В	1.429-2.856	Laggard:	lagging its industry base	ed on its high expos	ure and failure t	o manage significar	nt ESG risks		
	ccc	0.000-1.428	3							
Moody's ESG solutions	believes that	t a company in	gree to which companies integrating ESG factors into or shareholders over the i	to its business model and						
Refinitiv ESG rating	based on pu	ıblicly available	and objectively measure e and auditable data. The ta publicly. (Score ratings a	e score ranges from 0 to	100 on relative E	SG performar	nce and insufficie	ent degree of to		
S&P Global			re is a relative score mea in the same industry clas				of ESG risks, op	portunities, an	impacts	
Bloomberg	ESG Score		score is based on Bloor	ating the company's agg mberg's view of ESG fina the weights are determin	ancial materiality.	The score is	a weighted gener	ralized mean ((power mean)	

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION


Songklod Wongchai FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
03-Nov-2023 07-Feb-2024	BUY HOLD	12.00 12.00	29-Mar-2024 07-Nov-2024	BUY HOLD	12.00 8.20	-	-	-

Songklod Wongchai started covering this stock from 03-Nov-2023

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Genesis Fertility Center	GFC TB	THB 7.20	HOLD	ความเสี่ยงที่จะทำให้ประมาณการของเราต่ำกว่าคาด คือ เกิดวิกฤติด้านสาธารณะสุข เช่น โรดระบาดโค วิด หรือเกิตเหตุข้อพิพาทด้านกฎหมาย และต้นทุนในการรักษา โดยเฉพาะยาที่ใช้ในการรักษากรณีมี บุตรยากมีราคาสูงขึ้นกว่าคาด

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 11-Nov-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.